Consolidating the Digital Slide: How Agilent's $270M Proscia Acquisition Signals the End of Standalone Pathology AI
Dr. Dereck Mush, MD, MBA
Proscia
Enterprise digital pathology software and AI applications for laboratories and life sciences.
What they do
The company develops the Concentriq platform, which digitizes pathology workflows and integrates artificial intelligence to help laboratories and research organizations manage and analyze massive image datasets. It helps pathologists diagnose cancer and other diseases with improved consistency. In October 2026 Agilent agreed to acquire Proscia for $240M in cash at closing plus up to $30M in milestones; Proscia serves more than 4,000 laboratories, hospitals and clinics and was named 2026 Best in KLAS for Digital Pathology.
The record
- Vertical
- Imaging & Diagnostics
- Sub-segment
- Digital pathology software
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Philadelphia, USA
- Region
- North America
- Founded
- 2014
- Total funding
- $83M raised
Notable investors: Highland Capital Partners, Scale Venture Partners, Sorensen Capital, Hitachi Ventures.
Also in Imaging & Diagnostics
Related on The Signal
Dr. Dereck Mush, MD, MBA
The AI-Native Practice Playbook: Why Epsilon Health Built a Medical Group Instead of Selling Software
Dr. Dereck Mush, MD, MBA
Digital Pathology Finally Has FDA-Cleared AI. Why Hospital Adoption Is Still Spotty
Dr. Dereck Mush, MD, MBA
Mobile Clinics Lean on Scheduling Software to Reach the Patients Who Need Them Most
Dr. Dereck Mush, MD, MBA